DamonLBassDO

PubMed

• 4 citations
  Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.
  Fengchun Zhang, Jie Zheng, Yang Li, Guochun Wang, Mingjun Wang, Yin Su, Jieruo Gu, Xingfu Li, Myron Chu, Paula Curtis, Kathleen DeRose, Regina Kurrasch, Jenny Lowe, Pa...> ;RMD Open. 2022 Apr 1
• 8 citations
  Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
  , , , , , , , , , , , , , , , , > ;RMD Open. 2021 Sep 1
• 14 citations
  Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Ko...
  Yoshiya Tanaka, Sang Cheol Bae, Paula S. Curtis, Myron Chu, Kathleen DeRose, Beulah Ji, Regina Kurrasch, Jenny Lowe, Paige Meizlik, David M. Roth> ;RMD Open. 2021 Jul 1
• 15 citations
  Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multic...
  Sheikh, S., Scheinberg, M., Wei, J., Tegzova, D., Stohl, W., de Toledo, R., Mucenic, T., Banfi, M., Maksimowicz-McKinnon, K., Abud-Mendoza, C., Navarra, S., Garcia, M....> ;The Lancet. Rheumatology. 2021 Feb 1
• 5 citations
  Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the p...
  Toni Maslen, Ian N. Bruce, David D'Cruz, Mihaela Ianosev, Christel Wilkinson, David M. Roth> ;Lupus Science & Medicine. 2021 Feb 1
• 10 citations
  Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study
  Ronald F van Vollenhoven, William Stohl, Richard Furie, N.L. Fox, J. Groark, Damon Bass, Milena Kurtinecz, Bonnie F Pobiner, William J Eastman, Tania Gonzalez‑Rivera, ...> ;Lupus Science & Medicine. 2018 Nov 1
• 172 citations
  A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea
  Fengchun Zhang, Sang Cheol Bae, Damon Bass, Myron Chu, Sally Egginton, David Gordon, David M. Roth, Jie Zheng, Yoshiya Tanaka> ;Annals of the Rheumatic Diseases. 2018 Jan 2
• Join now to see all